Extensions to the Visual Predictive Check to facilitate model performance evaluation
暂无分享,去创建一个
Meindert Danhof | Teun M. Post | Jan I. Freijer | Bart A. Ploeger | T. Post | B. Ploeger | M. Danhof | J. Freijer
[1] N. Holford,et al. Population Pharmacokinetics of Humanized Monoclonal Antibody HuCC49ΔCH2 and Murine Antibody CC49 in Colorectal Cancer Patients , 2007, Journal of clinical pharmacology.
[2] L B Sheiner,et al. Pharmacokinetic/pharmacodynamic modeling in drug development. , 2000, Annual review of pharmacology and toxicology.
[3] C Garnett,et al. Impact of Pharmacometric Reviews on New Drug Approval and Labeling Decisions—a Survey of 31 New Drug Applications Submitted Between 2005 and 2006 , 2007, Clinical pharmacology and therapeutics.
[4] J. Windeler,et al. Intention-to-treat: methods for dealing with missing values in clinical trials of progressively deteriorating diseases. , 2001, Statistics in medicine.
[5] Geert Verbeke,et al. Multiple Imputation for Model Checking: Completed‐Data Plots with Missing and Latent Data , 2005, Biometrics.
[6] W. Winter,et al. A Mechanism-based Disease Progression Model for Comparison of Long-term Effects of Pioglitazone, Metformin and Gliclazide on Disease Processes Underlying Type 2 Diabetes Mellitus , 2006, Journal of Pharmacokinetics and Pharmacodynamics.
[7] Mark E. Sale,et al. A Joint Model for Nonlinear Longitudinal Data with Informative Dropout , 2003, Journal of Pharmacokinetics and Pharmacodynamics.
[8] W Ewy,et al. Model‐based Drug Development , 2007, Clinical pharmacology and therapeutics.
[9] France Mentré,et al. Metrics for External Model Evaluation with an Application to the Population Pharmacokinetics of Gliclazide , 2006, Pharmaceutical Research.
[10] N H Holford,et al. Drug treatment effects on disease progression. , 2001, Annual review of pharmacology and toxicology.
[11] Steven G. Woolfrey,et al. Analysis of Toxicokinetic Data Using NONMEM: Impact of Quantification Limit and Replacement Strategies for Censored Data , 2001, Journal of Pharmacokinetics and Pharmacodynamics.
[12] R. Urquhart,et al. Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes. , 2005, Diabetes care.
[13] Nicholas H. G. Holford,et al. The Visual Predictive Check Superiority to Standard Diagnostic (Rorschach) Plots , 2005 .
[14] L Aarons. Pharmacokinetic and pharmacodynamic modelling in drug development. , 1999, Statistical methods in medical research.
[15] Jogarao V. S. Gobburu,et al. A new equivalence based metric for predictive check to qualify mixed-effects models , 2005, The AAPS Journal.
[16] L. Sheiner,et al. Evaluating Pharmacokinetic/Pharmacodynamic Models Using the Posterior Predictive Check , 2001, Journal of Pharmacokinetics and Pharmacodynamics.
[17] J. Nutt,et al. Disease Progression and Pharmacodynamics in Parkinson Disease – Evidence for Functional Protection with Levodopa and Other Treatments , 2006, Journal of Pharmacokinetics and Pharmacodynamics.
[18] L B Sheiner,et al. Learning versus confirming in clinical drug development , 1997, Clinical pharmacology and therapeutics.
[19] Adrian Dunne,et al. Analysis of Nonrandomly Censored Ordered Categorical Longitudinal Data from Analgesic Trials , 1997 .
[20] France Mentré,et al. Prediction Discrepancies for the Evaluation of Nonlinear Mixed-Effects Models , 2006, Journal of Pharmacokinetics and Pharmacodynamics.